[{"id":"53796a59-6a92-429e-a054-ab12ec9e66b8","acronym":"","url":"https://clinicaltrials.gov/study/NCT06855849","created_at":"2025-06-07T15:05:19.495Z","updated_at":"2025-06-07T15:05:19.495Z","phase":"Phase 2","brief_title":"An Open-label, Single-arm, Multicenter Phase II Study to Evaluate the Efficacy of Amivantamab in Combination With FOLFIRI as a Second-line Treatment in Patients With RAS/BRAF Wild-type Advanced Colorectal Cancer Progressing on Prior Anti-EGFR Based Treatment.","source_id_and_acronym":"NCT06855849","lead_sponsor":"Yonsei University","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • irinotecan • Rybrevant (amivantamab-vmjw) • leucovorin calcium"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 85","initiation":"Initiation: 05/01/2025","start_date":" 05/01/2025","primary_txt":" Primary completion: 05/01/2027","primary_completion_date":" 05/01/2027","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2025-03-04"},{"id":"0db89e9b-db2b-43cc-83d7-77deb9d111cd","acronym":"SCOUT","url":"https://clinicaltrials.gov/study/NCT02637687","created_at":"2021-01-17T17:20:37.992Z","updated_at":"2025-02-25T12:26:24.234Z","phase":"Phase 1/2","brief_title":"A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children","source_id_and_acronym":"NCT02637687 - SCOUT","lead_sponsor":"Bayer","biomarkers":" NTRK3 • ETV6 • NTRK","pipe":" | ","alterations":" NTRK positive • NTRK fusion","tags":["NTRK3 • ETV6 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK positive • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Vitrakvi (larotrectinib) • pemetrexed • Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 154","initiation":"Initiation: 12/16/2015","start_date":" 12/16/2015","primary_txt":" Primary completion: 07/20/2024","primary_completion_date":" 07/20/2024","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2025-02-24"},{"id":"6fa58343-5f41-4e65-b9b7-ed2e1d17361f","acronym":"LUNG-MAP SUB-STUDY","url":"https://clinicaltrials.gov/study/NCT06116682","created_at":"2023-11-03T20:12:32.614Z","updated_at":"2025-02-25T14:10:16.796Z","phase":"Phase 2","brief_title":"Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)","source_id_and_acronym":"NCT06116682 - LUNG-MAP SUB-STUDY","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" EGFR • HER-2 • KRAS • BRAF • ALK • MET • RET • ROS1 • NTRK","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • HER-2 mutation • MET amplification • EGFR T790M • MET exon 14 mutation • ALK fusion • ROS1 fusion • RET rearrangement","tags":["EGFR • HER-2 • KRAS • BRAF • ALK • MET • RET • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • HER-2 mutation • MET amplification • EGFR T790M • MET exon 14 mutation • ALK fusion • ROS1 fusion • RET rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rybrevant (amivantamab-vmjw) • Rybrevant Faspro (amivantamab and hyaluronidase-lpuj)"],"overall_status":"Recruiting","enrollment":" Enrollment 88","initiation":"Initiation: 11/19/2024","start_date":" 11/19/2024","primary_txt":" Primary completion: 05/31/2028","primary_completion_date":" 05/31/2028","study_txt":" Completion: 05/31/2028","study_completion_date":" 05/31/2028","last_update_posted":"2025-02-19"},{"id":"76c77ff7-c81e-43e4-ae4a-aaef8350e163","acronym":"COCOON","url":"https://clinicaltrials.gov/study/NCT06120140","created_at":"2023-11-07T16:14:24.835Z","updated_at":"2025-02-25T14:42:28.607Z","phase":"Phase 2","brief_title":"Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib","source_id_and_acronym":"NCT06120140 - COCOON","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR L858R • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib) • Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) • minocycline"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 02/16/2024","start_date":" 02/16/2024","primary_txt":" Primary completion: 11/07/2025","primary_completion_date":" 11/07/2025","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2025-02-14"},{"id":"ecd3b97e-f85f-4235-ac7a-4003f3339215","acronym":"NEOpredict-EGF","url":"https://clinicaltrials.gov/study/NCT06784791","created_at":"2025-02-25T14:44:13.644Z","updated_at":"2025-02-25T14:44:13.644Z","phase":"Phase 2","brief_title":"Preoperative Amivantamab or Amivantamab and Carboplatin/pemetrexed Treatment in Patients with Resectable Non-small-cell Lung Cancer Harboring Oncogenic EGFR Mutations (NEOpredict-EGFR)","source_id_and_acronym":"NCT06784791 - NEOpredict-EGF","lead_sponsor":"University Hospital, Essen","biomarkers":" EGFR • CD8 • CD163 • CD4 • NCAM1 • CD68","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR • CD8 • CD163 • CD4 • NCAM1 • CD68"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 11/06/2024","start_date":" 11/06/2024","primary_txt":" Primary completion: 07/31/2027","primary_completion_date":" 07/31/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-14"},{"id":"13d717d6-af81-4d62-b82e-e808705b0f8a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04965090","created_at":"2021-07-16T13:53:19.792Z","updated_at":"2025-02-25T15:12:09.657Z","phase":"Phase 2","brief_title":"A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT04965090","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 43","initiation":"Initiation: 09/30/2021","start_date":" 09/30/2021","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2025-02-13"},{"id":"70cd0c5d-7d88-425d-9c89-b461c30c15c1","acronym":"AMIGO-1","url":"https://clinicaltrials.gov/study/NCT05299125","created_at":"2022-03-28T12:52:54.230Z","updated_at":"2025-02-25T15:19:41.079Z","phase":"Phase 2","brief_title":"Amivantamab, Lazertinib, and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers With Epidermal Growth Factor Receptor Mutations","source_id_and_acronym":"NCT05299125 - AMIGO-1","lead_sponsor":"Latin American Cooperative Oncology Group","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 05/24/2023","start_date":" 05/24/2023","primary_txt":" Primary completion: 01/30/2026","primary_completion_date":" 01/30/2026","study_txt":" Completion: 07/31/2027","study_completion_date":" 07/31/2027","last_update_posted":"2025-02-12"},{"id":"875dde5d-a068-44c0-a533-8d1880dcc9a8","acronym":"MARIPOSA","url":"https://clinicaltrials.gov/study/NCT04487080","created_at":"2021-01-18T21:32:24.291Z","updated_at":"2025-02-25T15:18:45.913Z","phase":"Phase 3","brief_title":"A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT04487080 - MARIPOSA","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1074","initiation":"Initiation: 09/30/2020","start_date":" 09/30/2020","primary_txt":" Primary completion: 08/11/2023","primary_completion_date":" 08/11/2023","study_txt":" Completion: 06/29/2027","study_completion_date":" 06/29/2027","last_update_posted":"2025-02-12"},{"id":"8b86d973-6a4a-4265-ab5b-f102925ec3cd","acronym":"PAPILLON","url":"https://clinicaltrials.gov/study/NCT04538664","created_at":"2021-01-18T21:43:09.446Z","updated_at":"2025-02-25T15:18:48.860Z","phase":"Phase 3","brief_title":"A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions","source_id_and_acronym":"NCT04538664 - PAPILLON","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 308","initiation":"Initiation: 10/13/2020","start_date":" 10/13/2020","primary_txt":" Primary completion: 05/03/2023","primary_completion_date":" 05/03/2023","study_txt":" Completion: 01/31/2026","study_completion_date":" 01/31/2026","last_update_posted":"2025-02-12"},{"id":"5f3b5bbb-9aff-4571-a252-57e8a1171808","acronym":"CHRYSALIS-2","url":"https://clinicaltrials.gov/study/NCT04077463","created_at":"2021-01-18T19:58:05.927Z","updated_at":"2025-02-25T15:34:28.760Z","phase":"Phase 1","brief_title":"A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer","source_id_and_acronym":"NCT04077463 - CHRYSALIS-2","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" EGFR • MET","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR expression • MET expression • EGFR exon 20 mutation","tags":["EGFR • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR expression • MET expression • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 701","initiation":"Initiation: 09/04/2019","start_date":" 09/04/2019","primary_txt":" Primary completion: 02/03/2025","primary_completion_date":" 02/03/2025","study_txt":" Completion: 06/03/2026","study_completion_date":" 06/03/2026","last_update_posted":"2025-02-11"},{"id":"aef3f3cb-aa50-40d2-b1b1-727aae5c68fd","acronym":"CHRYSALIS","url":"https://clinicaltrials.gov/study/NCT02609776","created_at":"2021-01-17T17:17:24.122Z","updated_at":"2025-02-25T15:33:33.328Z","phase":"Phase 1","brief_title":"Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT02609776 - CHRYSALIS","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" ALK • MET","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • EGFR exon 20 insertion • EGFR wild-type • MET exon 14 mutation • MET expression • EGFR exon 20 mutation • EGFR positive","tags":["ALK • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • EGFR exon 20 insertion • EGFR wild-type • MET exon 14 mutation • MET expression • EGFR exon 20 mutation • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 751","initiation":"Initiation: 05/24/2016","start_date":" 05/24/2016","primary_txt":" Primary completion: 01/31/2024","primary_completion_date":" 01/31/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-11"},{"id":"d34aa307-ae7e-44e1-9d9a-f7de8a535562","acronym":"PALOMA-2","url":"https://clinicaltrials.gov/study/NCT05498428","created_at":"2022-08-19T18:11:07.577Z","updated_at":"2025-02-25T15:19:56.526Z","phase":"Phase 2","brief_title":"A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05498428 - PALOMA-2","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR exon 20 mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib) • Rybrevant Faspro (amivantamab and hyaluronidase-lpuj)"],"overall_status":"Recruiting","enrollment":" Enrollment 390","initiation":"Initiation: 11/11/2022","start_date":" 11/11/2022","primary_txt":" Primary completion: 10/31/2025","primary_completion_date":" 10/31/2025","study_txt":" Completion: 08/05/2026","study_completion_date":" 08/05/2026","last_update_posted":"2025-02-11"},{"id":"f1064650-0259-4959-8f4b-9c77670f97c9","acronym":"OrigAMI-2","url":"https://clinicaltrials.gov/study/NCT06662786","created_at":"2025-02-25T15:45:58.168Z","updated_at":"2025-02-25T15:45:58.168Z","phase":"Phase 3","brief_title":"A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer","source_id_and_acronym":"NCT06662786 - OrigAMI-2","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • irinotecan • Rybrevant (amivantamab-vmjw) • leucovorin calcium • levoleucovorin calcium"],"overall_status":"Recruiting","enrollment":" Enrollment 1000","initiation":"Initiation: 10/18/2024","start_date":" 10/18/2024","primary_txt":" Primary completion: 12/15/2028","primary_completion_date":" 12/15/2028","study_txt":" Completion: 12/15/2032","study_completion_date":" 12/15/2032","last_update_posted":"2025-02-10"},{"id":"cb4879f1-5eee-438d-aef4-7efd2ba1fd90","acronym":"OrigAMI-3","url":"https://clinicaltrials.gov/study/NCT06750094","created_at":"2025-02-25T17:04:29.028Z","updated_at":"2025-02-25T17:04:29.028Z","phase":"Phase 3","brief_title":"A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy","source_id_and_acronym":"NCT06750094 - OrigAMI-3","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • irinotecan • Rybrevant (amivantamab-vmjw) • leucovorin calcium • levoleucovorin calcium"],"overall_status":"Recruiting","enrollment":" Enrollment 700","initiation":"Initiation: 12/12/2024","start_date":" 12/12/2024","primary_txt":" Primary completion: 12/15/2027","primary_completion_date":" 12/15/2027","study_txt":" Completion: 04/13/2029","study_completion_date":" 04/13/2029","last_update_posted":"2025-02-03"},{"id":"cc8ae39c-8d2c-409b-90ee-a7c5c6b73c19","acronym":"MARIPOSA-2","url":"https://clinicaltrials.gov/study/NCT04988295","created_at":"2021-08-03T18:53:03.618Z","updated_at":"2024-07-02T16:35:01.929Z","phase":"Phase 3","brief_title":"A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure","source_id_and_acronym":"NCT04988295 - MARIPOSA-2","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 776","initiation":"Initiation: 11/17/2021","start_date":" 11/17/2021","primary_txt":" Primary completion: 07/10/2023","primary_completion_date":" 07/10/2023","study_txt":" Completion: 12/08/2025","study_completion_date":" 12/08/2025","last_update_posted":"2024-05-22"},{"id":"e692155b-fbe6-47e3-bd38-48bfcb5e6c8e","acronym":"OSTARA","url":"https://clinicaltrials.gov/study/NCT05801029","created_at":"2023-04-06T14:03:13.725Z","updated_at":"2024-07-02T16:35:02.179Z","phase":"Phase 2","brief_title":"A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations","source_id_and_acronym":"NCT05801029 - OSTARA","lead_sponsor":"AstraZeneca","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • Rybrevant (amivantamab-vmjw)"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 07/18/2023","start_date":" 07/18/2023","primary_txt":" Primary completion: 04/30/2028","primary_completion_date":" 04/30/2028","study_txt":" Completion: 04/30/2028","study_completion_date":" 04/30/2028","last_update_posted":"2024-05-21"},{"id":"f0da2c69-063d-412e-8403-ded1fd245a6b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05845671","created_at":"2023-05-06T15:04:41.894Z","updated_at":"2024-07-02T16:35:04.160Z","phase":"Phase 1/2","brief_title":"Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations","source_id_and_acronym":"NCT05845671","lead_sponsor":"University of Colorado, Denver","biomarkers":" RET • ROS1","pipe":" | ","alterations":" RET fusion • ALK fusion • ROS1 fusion","tags":["RET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion • ALK fusion • ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rybrevant (amivantamab-vmjw)"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 07/11/2023","start_date":" 07/11/2023","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 01/01/2028","study_completion_date":" 01/01/2028","last_update_posted":"2024-05-13"},{"id":"a3747950-095a-48c6-aa37-bde9bcafea6d","acronym":"","url":"https://clinicaltrials.gov/study/NCT06083857","created_at":"2023-10-16T16:13:46.888Z","updated_at":"2024-07-02T16:35:06.404Z","phase":"Phase 1/2","brief_title":"PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer","source_id_and_acronym":"NCT06083857","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" MET","pipe":" | ","alterations":" MET amplification • MET exon 14 mutation • MET overexpression","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • MET exon 14 mutation • MET overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rybrevant (amivantamab-vmjw) • Tepmetko (tepotinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 04/30/2024","start_date":" 04/30/2024","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2024-05-02"},{"id":"7dee7c32-8472-406f-8f72-6b586e2ef1c0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05601973","created_at":"2022-11-05T15:14:26.887Z","updated_at":"2024-07-02T16:35:11.171Z","phase":"Phase 2","brief_title":"AMAZE-lung: Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI","source_id_and_acronym":"NCT05601973","lead_sponsor":"ETOP IBCSG Partners Foundation","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 03/27/2023","start_date":" 03/27/2023","primary_txt":" Primary completion: 03/30/2026","primary_completion_date":" 03/30/2026","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2024-04-05"},{"id":"a716c9c6-6239-4e8b-853c-86fb57b7bc7c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05117931","created_at":"2021-11-11T12:53:37.831Z","updated_at":"2024-07-02T16:35:16.106Z","phase":"Phase 2","brief_title":"A Study of Amivantamab in People With Esophagogastric Cancer","source_id_and_acronym":"NCT05117931","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" HER-2","pipe":" | ","alterations":" MET amplification • EGFR amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • EGFR amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rybrevant (amivantamab-vmjw)"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 12/02/2021","start_date":" 12/02/2021","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2024-03-06"},{"id":"366da270-8f09-44d6-be12-90adac16a8b2","acronym":"","url":"https://clinicaltrials.gov/study/NCT06085729","created_at":"2023-10-17T15:12:33.301Z","updated_at":"2024-07-02T16:35:16.807Z","phase":"Phase 1/2","brief_title":"Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)","source_id_and_acronym":"NCT06085729","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • PTEN • RB1","pipe":" | ","alterations":" TP53 mutation • PTEN mutation • LDH elevation","tags":["TP53 • PTEN • RB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • PTEN mutation • LDH elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Rybrevant (amivantamab-vmjw) • Tepmetko (tepotinib) • cabazitaxel • Hepacid (pegargiminase)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 02/29/2024","start_date":" 02/29/2024","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2024-03-01"},{"id":"c91e80f5-f431-4bab-af26-4beadd1b4cc2","acronym":"RESAMEX","url":"https://clinicaltrials.gov/study/NCT06247826","created_at":"2024-02-08T14:19:17.602Z","updated_at":"2024-07-02T16:35:20.180Z","phase":"","brief_title":"Mechanisms of Resistance to Amivantamab in Patients With NSCLC With EGFR Exon 20 Insertion","source_id_and_acronym":"NCT06247826 - RESAMEX","lead_sponsor":"Groupe Francais De Pneumo-Cancerologie","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rybrevant (amivantamab-vmjw)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 01/15/2024","start_date":" 01/15/2024","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2024-02-08"},{"id":"869cd105-4da3-41c2-9a75-36bbb7499d2a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02623751","created_at":"2021-01-18T12:45:00.550Z","updated_at":"2024-07-02T16:36:08.514Z","phase":"Phase 1","brief_title":"Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer","source_id_and_acronym":"NCT02623751","lead_sponsor":"Kyowa Kirin Co., Ltd.","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw) • exemestane • Lazcluze (lazertinib) • Jingzhuda (entinostat)"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 11/01/2015","start_date":" 11/01/2015","primary_txt":" Primary completion: 10/01/2020","primary_completion_date":" 10/01/2020","study_txt":" Completion: 10/01/2020","study_completion_date":" 10/01/2020","last_update_posted":"2022-06-21"},{"id":"f8a40192-1e49-4bae-814e-984b8d8535ec","acronym":"","url":"https://clinicaltrials.gov/study/NCT04599712","created_at":"2021-01-19T20:30:12.955Z","updated_at":"2024-07-02T16:36:28.546Z","phase":"","brief_title":"Pre-Approval Access With Amivantamab (JNJ-61186372) in Participants With Metastatic Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT04599712","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR exon 20 insertion • EGFR exon 20 mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR exon 20 insertion • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rybrevant (amivantamab-vmjw)"],"overall_status":"Approved for marketing","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2021-06-29"}]